Navigation Links
Surface Logix, Inc. to Present at the Piper Jaffray Health Care Conference
Date:11/26/2007

BOSTON, Nov. 26 /PRNewswire/ -- Surface Logix, Inc. today announced that Jim Mahoney, President and Chief Executive Officer, will present an update of the company's drug development pipeline at the 19th Annual Piper Jaffray Health Care Conference being held November 27-29, 2007 at The Pierre Hotel in New York City. Mr. Mahoney's presentation will take place on Wednesday, November 28, 2007 at 2:50 PM EST.

Surface Logix currently has two programs in human clinical trials with a third program in the IND preparation stage. Mr. Mahoney will discuss the latest results for SLx-2101 and SLx-4090. SLx-2101, a second-generation PDE5 inhibitor designed to address cardiovascular indications, is currently in two separate Phase 2a trials, one in hypertension and another in Raynaud's syndrome. SLx-4090, a first-in-class enterocyte-specific MTP inhibitor for the treatment of dyslipidemia and potentially other indications, is also in Phase 2a.

About Surface Logix, Inc.

Surface Logix, Inc. uses its expertise in biophysical chemistry to create and develop novel small molecule drugs (NCEs) with superior drug-like properties that are clearly differentiated from competitive products. The company is advancing multiple internal programs focused primarily on cardiovascular, metabolic, oncologic and fibrotic diseases. For more information, please visit http://www.surfacelogix.com.

Contact:

Leland Webster, Ph.D., M.B.A.

Surface Logix Inc.

Vice President, Corporate Development

617.746.8520

Media:

Sarah Cavanaugh

MacDougall Biomedical Communications, Inc.

scavanaugh@macbiocom.com

508.647.0209


'/>"/>
SOURCE Surface Logix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
2. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
3. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
11. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Following receiving CE Marking in ... s AMAR is a major milestone for the country where the ... ound care market in Israel ... for inclusion in the National Health Basket , Israel ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment ...
(Date:2/24/2017)... and Markets has announced the addition of the "Hemophilia Drugs Price ... ... Analysis and Strategies - 2016, provides drug pricing data and benchmarks in ... What are the key drugs marketed for Hemophilia ... market? What are the unit prices and annual treatment ...
(Date:2/24/2017)... 24, 2017 Medical information groups within ... their self-service capabilities to manage inquiries from external ... New research from consulting leader Best Practices, ... self-service website portals where HCPs can sign on ... of many findings to emerge from the new ...
Breaking Medicine Technology:
(Date:2/26/2017)... , ... February 26, 2017 , ... ... for entries to the 7th Edition of International Social Design Awards. , ... Professionals, Product Designers, System Designers, Governments and Institutions worldwide with realized projects and ...
(Date:2/26/2017)... Philadelphia, PA (PRWEB) , ... February 26, 2017 , ... ... products and services with Pay-For-Performance B2B Marketing. B2B Sellers will now only pay for ... , Robert Hennessey, the founder of IndustryArchive.Org, said, “Given the new reality that B2B ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... disease (PD) in persons with a specific LRRK2 mutation, according to a study ... Previous studies have provided evidence of a link between pesticides and incidence of ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official ... (ILTM) show in Cannes (France), XO Private has initiated a second print-run of its ... measures almost a metre across when open, weighs in at more than six kilos, ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age is ... University predict that 47 percent of all jobs in the United States may be ... “successful.” The day of the aggressive know-it-all who steamrolls over colleagues is drawing to ...
Breaking Medicine News(10 mins):